Inhibitor of polyamine catabolism MDL72.527 restores the sensitivity to doxorubicin of monocytic leukemia Thp-1 cells infected with human cytomegalovirus-Reference-Cited by-同舟云学术

Inhibitor of polyamine catabolism MDL72.527 restores the sensitivity to doxorubicin of monocytic leukemia Thp-1 cells infected with human cytomegalovirus

Published:2019-03 Issue: Volume:158 Page:82-89
ISSN:0300-9084
Container-title:Biochimie
language:en
Short-container-title:Biochimie

Author:

Fedorova Natalia E.^ORCID,Chernoryzh Yana Yu^ORCID,Vinogradskaya Galina R.,Emelianova Svetlana S.,Zavalyshina Larisa E.,Yurlov Kirill I.^ORCID,Zakirova Natalia F.,Verbenko Valery N.,Kochetkov Sergey N.,Kushch Alla A.^ORCID,Ivanov Alexander V.^ORCID

Funder

Russian Foundation for Basic Research

Russian Science Foundation

Publisher

Elsevier BV

Subject

General Medicine,Biochemistry

Reference55 articles.

1. Childhood and adolescent cancer statistics, 2014;Ward;Ca - Cancer J. Clin.,2014

2. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep;Woods;Pediatr. Blood Canc.,2006

3. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study;Gorman;Pediatr. Blood Canc.,2010

4. Pediatric acute myeloid leukemia: towards high-quality cure of all patients;Kaspers;Haematologica,2007

5. Mechanisms, function and clinical applications of DNp73;Di;Cell Cycle,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polyamine Catabolism Revisited: Acetylpolyamine Oxidase Plays a Minor Role due to Low Expression;Cells;2024-07-01

2. One-Carbon and Polyamine Metabolism as Cancer Therapy Targets;Biomolecules;2022-12-19

3. 2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus;Cancers;2022-11-15

4. Mechanisms of Survival of Cytomegalovirus-Infected Tumor Cells;Molecular Biology;2022-10

5. Metabolism and function of polyamines in cancer progression;Cancer Letters;2021-10